At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 185 enrolled
Drug / intervention
risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating risankizumab and placebo for risankizumab for Arthritis, Psoriatic. Completed, enrolled 185 participants.
Detailed Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further clinical trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Psoriatic
Countries--
CollaboratorsBoehringer Ingelheim
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionMay 2017
Study CompletionAug 2017
TodayJul 2026
First PostedMar 25, 2016
Enrollment StartApr 1, 2016
Primary CompletionMay 1, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.3 years ago
Interventions
risankizumabdrug
Risankizumab administered by SC injection
placebo for risankizumabdrug
Placebo for risankizumab administered by SC injection